Since GSK3β is known to be inactivated by AKT or ERK [25, 43], our work suggests a direct role of the GSK3β-EZH2 pathway in this scenario and offers a rationale for enhancing GSK3β activity and/or targeting EZH2 in anti-cancer therapy. Here, AKT1 is linked to cancer.